Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;335:386 (25 August), doi:10.1136/bmj.39244.692442.55 (published 4 July 2007)
Giovanni Montini, consultant in paediatric nephrology1, Antonella Toffolo, consultant in paediatrics2, Pietro Zucchetta, consultant in nuclear medicine3, Roberto Dall'Amico, consultant in paediatrics4, Daniela Gobber, senior lecturer in epidemiology5, Alessandro Calderan, general practitioner6, Francesca Maschio, consultant in paediatrics7, Luigi Pavanello, consultant in paediatrics8, Pier Paolo Molinari, consultant in paediatrics9, Dante Scorrano, consultant in paediatrics10, Sergio Zanchetta, consultant in paediatrics11, Walburga Cassar, consultant in paediatrics12, Paolo Brisotto, consultant in paediatrics13, Andrea Corsini, consultant in paediatrics14, Stefano Sartori, fellow in paediatrics1, Liviana Da Dalt, associate professor, paediatric emergency15, Luisa Murer, consultant in paediatric nephrology1, Graziella Zacchello, associate professor, paediatric nephrology1
1 Nephrology, Dialysis, and Transplant Unit, Paediatric Department, Azienda Ospedaliera-University of Padua, 35128 Padua, Italy, 2 Paediatric Unit, Oderzo Hospital, Italy, 3 Nuclear Medicine Department, Azienda Ospedaliera-University of Padua, 4 Paediatric Unit, Thiene Hospital, Italy, 5 Epidemiology Unit, Azienda Ospedaliera-University of Padua, 6 San Donà di Piave, Venice, 7 Paediatric Unit, Mestre Hospital, Italy, 8 Paediatric Unit, Castelfranco Veneto Hospital, Italy , 9 Paediatric Unit, Bologna Hospital, Italy , 10 Paediatric Unit, Belluno Hospital, Italy , 11 Paediatric Unit, Soave Hospital, Italy , 12 Paediatric Unit, Bolzano Hospital, Italy , 13 Paediatric Unit, Montebelluna Hospital, Italy , 14 Paediatric Unit, Bentivoglio, Italy, 15 Emergency Unit, Paediatric Department, Azienda Ospedaliera-University of Padua
Correspondence to: G Montini montini{at}pediatria.unipd.it
Design Multicentre, randomised controlled, open labelled, parallel group, non-inferiority trial.
Setting 28 paediatric units in north east Italy.
Participants 502 children aged 1 month to <7 years with clinical pyelonephritis.
Intervention Oral co-amoxiclav (50 mg/kg/day in three doses for 10 days) or parenteral ceftriaxone (50 mg/kg/day in a single parenteral dose) for three days, followed by oral co-amoxiclav (50 mg/kg/day in three divided doses for seven days).
Main outcomes measures Primary outcome was the rate of renal scarring. Secondary measures of efficacy were time to defervescence (<37°C), reduction in inflammatory indices, and percentage with sterile urine after 72 hours. An exploratory subgroup analysis was conducted in the children in whom pyelonephritis was confirmed by dimercaptosuccinic acid (DMSA) scintigraphy within 10 days after study entry.
Results Intention to treat analysis showed no significant differences between oral (n=244) and parenteral (n=258) treatment, both in the primary outcome (scarring scintigraphy at 12 months 27/197 (13.7%) v 36/203 (17.7%), difference in risk –4%, 95% confidence interval –11.1% to 3.1%) and secondary outcomes (time to defervescence 36.9 hours (SD 19.7) v 34.3 hours (SD 20), mean difference 2.6 (–0.9 to 6.0); white cell count 9.8x109/l (SD 3.5) v 9.5x109/l (SD 3.1), mean difference 0.3 (–0.3 to 0.9); percentage with sterile urine 185/186 v 203/204, risk difference –0.05% (–1.5% to 1.4%)). Similar results were found in the subgroup of 278 children with confirmed acute pyelonephritis on scintigraphy at study entry.
Conclusions Treatment with oral antibiotics is as effective as parenteral then oral treatment in the management of the first episode of clinical pyelonephritis in children.
Trial registration Clinical Trials NCT00161330 [ClinicalTrials.gov] .
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+